PMID- 35740647
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 12
DP  - 2022 Jun 16
TI  - Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or 
      More Systemic Treatments: A Multicenter Study.
LID - 10.3390/cancers14122975 [doi]
LID - 2975
AB  - BACKGROUND: The present study aimed to clarify the efficacy and safety of 
      ramucirumab in a real-world setting, including patients who experienced two or 
      more systemic treatments or whose hepatic reserve was deteriorated. METHODS: In 
      total, 79 patients with hepatocellular carcinoma (HCC) from 14 institutes 
      throughout Japan were retrospectively analyzed. The response was evaluated using 
      the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and AEs 
      were recorded according to the Common Terminology Criteria for AEs (CTCAE) 
      version 5.0. RESULTS: Median overall survival (OS) in the total cohort was 7.5 
      months (m). Median OS was 8.8 m in patients who were administered ramucirumab as 
      a second-line treatment, while it was 7.3 m in third- or later-line treatment. 
      Progression-free survival rates in the second- and third- or later-line therapies 
      were 3.2 m and 3.2 m, respectively. The disease control rate (DCR) in the study 
      was 43%. There were no statistically significant differences in DCR between the 
      treatment courses. Regarding adverse events (AEs), the development of ascites was 
      observed significantly more frequently in modified albumin-bilirubin (mALBI) 2b/3 
      patients than in mALBI 1/2a patients (54.5% vs. 25.0%, p = 0.03). CONCLUSIONS: 
      Ramucirumab is useful as a second-line therapy and feasible as a third- or 
      later-line treatment for HCC.
FAU - Yasui, Yutaka
AU  - Yasui Y
AUID- ORCID: 0000-0002-6117-4990
AD  - Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 
      Tokyo 180-8610, Japan.
FAU - Kurosaki, Masayuki
AU  - Kurosaki M
AUID- ORCID: 0000-0001-7016-8931
AD  - Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 
      Tokyo 180-8610, Japan.
FAU - Tsuchiya, Kaoru
AU  - Tsuchiya K
AUID- ORCID: 0000-0003-0436-5915
AD  - Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 
      Tokyo 180-8610, Japan.
FAU - Hayakawa, Yuka
AU  - Hayakawa Y
AD  - Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 
      Tokyo 180-8610, Japan.
FAU - Hasebe, Chitomi
AU  - Hasebe C
AD  - Department of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Asahikawa 
      070-8530, Japan.
FAU - Abe, Masami
AU  - Abe M
AD  - Department of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Asahikawa 
      070-8530, Japan.
FAU - Ogawa, Chikara
AU  - Ogawa C
AUID- ORCID: 0000-0002-4534-6692
AD  - Department of Gastroenterology, Takamatsu Red Cross Hospital, Takamatsu 760-0017, 
      Japan.
FAU - Joko, Kouji
AU  - Joko K
AD  - Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, 
      Matsuyama 790-8524, Japan.
FAU - Ochi, Hironori
AU  - Ochi H
AD  - Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, 
      Matsuyama 790-8524, Japan.
FAU - Tada, Toshifumi
AU  - Tada T
AD  - Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital, 
      Himeji 670-8540, Japan.
FAU - Nakamura, Shinichiro
AU  - Nakamura S
AD  - Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital, 
      Himeji 670-8540, Japan.
FAU - Furuta, Koichiro
AU  - Furuta K
AD  - Department of Internal Medicine, Masuda Red Cross Hospital, Masuda 698-8501, 
      Japan.
FAU - Kimura, Hiroyuki
AU  - Kimura H
AD  - Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 
      605-0981, Japan.
FAU - Tsuji, Keiji
AU  - Tsuji K
AD  - Department of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb 
      Survivors Hospital, Hiroshima 730-8619, Japan.
FAU - Kojima, Yuji
AU  - Kojima Y
AD  - Department of Gastroenterology, Japanese Red Cross Ise Hospital, Ise 516-8512, 
      Japan.
FAU - Akahane, Takehiro
AU  - Akahane T
AD  - Department of Gastroenterology, Ishinomaki Red Cross Hospital, Ishinomaki 
      986-8522, Japan.
FAU - Tamada, Takashi
AU  - Tamada T
AD  - Department of Gastroenterology, Takatsuki Red Cross Hospital, Takatsuki 569-1096, 
      Japan.
FAU - Uchida, Yasushi
AU  - Uchida Y
AD  - Department of Gastroenterology, Matsue Red Cross Hospital, Matsue 690-8506, 
      Japan.
FAU - Kondo, Masahiko
AU  - Kondo M
AD  - Department of Gastroenterology, Otsu Red Cross Hospital, Otsu 520-8511, Japan.
FAU - Mitsuda, Akeri
AU  - Mitsuda A
AD  - Department of Internal Medicine, Japanese Red Cross Tottori Hospital, Tottori 
      680-8517, Japan.
FAU - Izumi, Namiki
AU  - Izumi N
AD  - Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 
      Tokyo 180-8610, Japan.
CN  - Japanese Red Cross Liver Study Group
LA  - eng
GR  - none/Miyakawa Memorial Research Foundation/
GR  - none/Uehara Memorial Foundation/
GR  - JP20fk0210067h0001/Japan Agency for Medical Research and Development/
PT  - Journal Article
DEP - 20220616
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9221496
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - molecularly targeted agents
OT  - ramucirumab
COIS- Y.Y. received a grant from the Uehara Memorial Foundation and Miyakawa Memorial 
      Research Foundation. Y.Y. received a speaker's bureau from Eli Lilly, Chugai, 
      Eisai, and Takeda. M.K. (Masayuki Kurosaki) received speaker's bureau from 
      Gilead, AbbVie, Bayer, Eli Lilly, Chugai, Eisai, and Otsuka. K.T. received 
      speaker's bureau from Bayer, Chugai, Takeda, Eisai, and Eli Lilly. N.I. received 
      speaker's bureau from Bayer, Chugai, Eli Lilly, Eisai, and Takeda. The funders 
      had no role in the design of the study; in the collection, analyses, or 
      interpretation of data; in the writing of the manuscript, or in the decision to 
      publish the results.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/25 06:01
PMCR- 2022/06/16
CRDT- 2022/06/24 01:07
PHST- 2022/05/22 00:00 [received]
PHST- 2022/06/11 00:00 [revised]
PHST- 2022/06/14 00:00 [accepted]
PHST- 2022/06/24 01:07 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/25 06:01 [medline]
PHST- 2022/06/16 00:00 [pmc-release]
AID - cancers14122975 [pii]
AID - cancers-14-02975 [pii]
AID - 10.3390/cancers14122975 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Jun 16;14(12):2975. doi: 10.3390/cancers14122975.